ArticleJournal of clinical medicine2023

RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia.

Teresa Maria Seccia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.